Cancer-Specific Survival Outcome in Early-Stage Young Breast Cancer: Evidence From the SEER Database Analysis

Li, Rui; Xiao, Zhesi; Hu, Daixing; Luo, Haojun; Yin, Guang; Feng, Yang; Min, Yu

doi:10.3389/fendo.2021.811878

Cited by 14 publications

(13 citation statements)

References 42 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining variables were also displayed as the year of diagnosis (2010–2013 and 2014–2017), race (White, Black, and Asian/Alaska Indian), marital status (married, separated, and never married or unmarried), grade/differentiation (I/well, II/moderate, and III+IV/poor+un), T stage (T1a, T1b, T2, T3a, and T3b), and FIGO stage (IIIC1 and IIIC2). Lastly, we randomly split these patients into the training and validation cohorts with a ratio of 7:3 as indicated by the previous studies ( 19 , 20 ).…”

Section: Methodsmentioning

confidence: 99%

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients

Yang¹,

Yang²,

Kou³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThis study aimed to develop a nomogram to predict the survival for stage IIIC endometrial cancer (EC) patients with adjuvant radiotherapy (ART) alone and personalize recommendations for the following adjuvant chemotherapy (ACT).MethodsIn total, 746 stage IIIC EC patients with ART alone were selected from the Surveillance, Epidemiology, and End Results (SEER) registry. Cox regression analysis was performed to identify independent risk factors. A nomogram was developed accordingly, and the area under the receiver operating characteristic curve (AUC) and C-index were implemented to assess the predictive power. The patients were divided into different risk strata based on the total points derived from the nomogram, and survival probability was compared between each risk stratus and another SEER-based cohort of stage IIIC EC patients receiving ART+ACT (cohort ART+ACT).ResultsFive independent predictors were included in the model, which had favorable discriminative power both in the training (C-index: 0.732; 95% CI: 0.704–0.760) and validation cohorts (C-index: 0.731; 95% CI: 0.709–0.753). The patients were divided into three risk strata (low risk <135, 135 ≤ middle risk ≤205, and high risk >205), where low-risk patients had survival advantages over patients from cohort ART+ACT (HR: 0.45, 95% CI: 0.33–0.61, P < 0.001). However, the middle- and high-risk patients were inferior to patients from cohort ART+ACT in survival (P < 0.001).ConclusionA nomogram was developed to exclusively predict the survival for stage IIIC EC patients with ART alone, based on which the low-risk patients might be perfect candidates to omit the following ACT. However, the middle- and high-risk patients would benefit from the following ACT.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients

Yang¹,

Yang²,

Kou³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…The prognosis of Bcafad depends on the grade and stage at the time of diagnosis [14]. The breast cancer survival in pediatrics is worse than in adults [15]. Currently our patient is 16 months after radiotherapy and there is no tumour recurrence.…”

Section: Discussionmentioning

confidence: 99%

Breast Carcinoma Arising in Fibroadenoma in a 15-Year-Old Girl; Diagnosis and Treatment Challenge

Razakanaivo¹,

Rakotoarivo²,

Andrianandrasana³

et al. 2022

JCT

View full text Add to dashboard Cite

Breast cancer in adolescents occurring in fibroadenomas is extremely rare. We report a case of right breast cancer in a 15-year-old female student diagnosed in 2020. This is the youngest reported case of breast cancer arising within fibroadenomas in the literature. The teenager has no personal or family history of cancer or known hereditary disease. Currently, there is no consensus on the management of breast cancer arising from adenofibromas in adolescents. Clinically, the tumor was inflammatory with axillary lymph node involvement (T4dN1M0). The fine-needle aspiration cytologic was suspicious of malignancy. The patient received four courses of neoadjuvant chemotherapy with 5-fluorouracil®, doxorubicin® and cyclosphosphamide®, followed by radical right mastectomy. The histological result of the surgical specimen is a non-specific carcinoma with a therapeutic effect greater than fifty percent. The patient received three courses of adjuvant chemotherapy with paclitaxel®. The adolescent underwent radiation therapy at her chest wall of 50 Gy and regional lymph node of 46 Gy. After radiotherapy, hormone therapy with Tamoxifene® at 20 mg per day was started. At 16 months from radiotherapy, there is no recurrence. The reconstruction of the right breast is planned in a few months.

show abstract

“…Surgical resection is the mainstay in the clinical treatment of solid tumors. However, because of the infiltrative nature of the malignancy, surgery may not remove the tumor cells completely. − Chemotherapy followed by surgery is the common treatment regimen in clinics for clearance of residual tumor cells. − Unfortunately, ∼33.3% of the postoperative tumor recurrence rate , and 10–40% of the 5 year survival rate − reveal that the clinical benefits are far from meeting expectations. Moreover, since the chemotherapeutic drugs usually suffer from strong side effects, the patients would suffer secondary physical and psychological harm during the treatment.…”

Section: Introductionmentioning

confidence: 99%

Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment Improvement

et al. 2023

View full text Add to dashboard Cite

In addition to residual cancer cells, the surgery resection-induced hyperinflammatory microenvironment is a key factor that leads to postsurgical cancer recurrence. Herein, we developed a dual-functional nanodrug Asp@cLANVs for postsurgical recurrence inhibition by loading the classical antiinflammatory drug aspirin (Asp) into cross-linked lipoic acid nanovesicles (cLANVs). The Asp@cLANVs can not only kill residual cancer cells at the doses comparable to common cytotoxic drugs by synergistic interaction between Asp and cLANVs, but also improve the postsurgical inflammatory microenvironment by their strongly synergistic anti-inflammation activity between Asp and cLANVs. Using mice bearing partially removed NCI-H460 tumors, we found that Asp@cLANVs gave a much lower recurrence rate (33.3%) compared with the first-line cytotoxic drug cisplatin (100%), and no mice died for at least 60 days after Asp@cLANV treatment while no mouse survived beyond day 43 in the cisplatin group. This dual-functional nanodrug constructs the first example that combines residual cancer cell killing and postoperative inflammation microenvironment improvement to suppress postsurgical cancer recurrence.

show abstract

Cancer-Specific Survival Outcome in Early-Stage Young Breast Cancer: Evidence From the SEER Database Analysis

Cited by 14 publications

References 42 publications

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients

Prognostic model for the exemption of adjuvant chemotherapy in stage IIIC endometrial cancer patients

Breast Carcinoma Arising in Fibroadenoma in a 15-Year-Old Girl; Diagnosis and Treatment Challenge

Aspirin-Loaded Cross-Linked Lipoic Acid Nanodrug Prevents Postoperative Tumor Recurrence by Residual Cancer Cell Killing and Inflammatory Microenvironment Improvement

Contact Info

Product

Resources

About